Profile
Raymond C.
Egan founded eMedguides.com, Inc., where he worked as Chairman.
Mr. Egan also formerly worked at Mirati Therapeutics, Inc., as Chairman from 2000 to 2010, Bristol Myers Squibb Co., as SVP-Healthcare Policy & New Business Development, Mead Johnson International Ltd., as President & General Manager, and Bristol Laboratories, Inc., as President & General Manager.
Mr. Egan received his Masters Business Admin degree from Syracuse University and undergraduate degree from Trinity College (Connecticut).
Former positions of Raymond C. Egan
Companies | Position | End |
---|---|---|
MIRATI THERAPEUTICS | Chairman | 2010-08-24 |
Bristol Laboratories, Inc. | President | - |
Mead Johnson International Ltd. | President | - |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
eMedguides.com, Inc.
eMedguides.com, Inc. Internet Software/ServicesTechnology Services eMedguides.com, Inc. provides an online and in-print internet directory for medical professionals. The company was founded by Daniel Goldenson and Raymond C. Egan and is headquartered in Princeton, NJ. | Founder | - |
Training of Raymond C. Egan
Syracuse University | Masters Business Admin |
Trinity College (Connecticut) | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Private companies | 4 |
---|---|
eMedguides.com, Inc.
eMedguides.com, Inc. Internet Software/ServicesTechnology Services eMedguides.com, Inc. provides an online and in-print internet directory for medical professionals. The company was founded by Daniel Goldenson and Raymond C. Egan and is headquartered in Princeton, NJ. | Technology Services |
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Mead Johnson International Ltd. | |
Bristol Laboratories, Inc. |
- Stock Market
- Insiders
- Raymond C. Egan